Myriad jumps after agreeing to sell prenatal health testing business

By Reuters News13:12 (UTC), 20 October 2026 Updated

** Shares of genetic testing company Myriad Genetics MYGN.O rise 20.7% to $5.05 premarket

** Co says it will sell its prenatal health testing business to Labcorp LH.N for $210 million in cash, plus the value of the inventory

** MYGN says the transaction is expected to be accretive to Myriad's revenue growth and profitability, while strengthening the balance sheet

** Labcorp expects the deal to add about $160 million in revenue in year one

** Myriad's prenatal portfolio features several genetic screening products designed for pregnancy and reproductive health

** MYGN stock down 31% YTD, as of last close

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.